DUTCH CARDIOTOX REGISTRY:

DUTCH CARDIOTOX REGISTRY: - DUTCH CARDIOTOX REGISTRY

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51393

Enrollment

1400

Registered

2022-06-28

Start date

2022-11-23

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: To be eligible participating in this study, patients must meet all the following criteria: • Patients who visit a specialized cardio-oncology unit. • Age >=18 years. • Written informed consent.

Exclusion criteria

Exclusion criteria: To improve the precision of cardiotoxicity definitions, patients with pre-existing symptomatic heart failure or left ventricular ejection fraction (LVEF)

Design outcomes

Primary

Measure	Time frame
Primary Objective: Register the incidence of cardiovascular toxicity of anticancer treatment.	—

Secondary

Measure	Time frame
Secondary Objectives: Identification of risk factors for cardiotoxicity. Improvement in the early detection of cardiotoxicity by imaging modalities such as echocardiography (or even cardiac CT or cardiac MRI when available). Describe long-term outcomes of patients that received anticancer regimens. Describe therapeutic approaches currently used in the treatment of cancer therapy-related cardiac dysfunction.	—

Measure

Time frame

Secondary Objectives: Identification of risk factors for cardiotoxicity. Improvement in the early detection of cardiotoxicity by imaging modalities such as echocardiography (or even cardiac CT or cardiac MRI when available). Describe long-term outcomes of patients that received anticancer regimens. Describe therapeutic approaches currently used in the treatment of cancer therapy-related cardiac dysfunction.

—

Countries

Netherlands

Outcome results